Endocrine Abstracts

Objective: Evaluate the efficacy and safety of adding lixisenatide to uncontrolled type 2 diabetic (T2DM) patients treated with insulin.Methods: A prospective uncontrolled study was designed. Primary endpoints (measured at 3 and 6 months) were change in HbA1c, weight, and insulin doses. Variables analysed were: HbA1c level, insulin and other hypoglycaemic agents doses, capillary glucose tests, number and type of hypoglycaemias, side effects and body comp...